The ~US$ 2.6 billion market for H2 receptor antagonist has been envisaged to witness lethargic growth prospects over the years to come., according to a recent research study of XploreMR. The research report for H2-receptor antagonists market elaborates the dynamics that are related to the growth and fragmented nature of the market. The market is expected to expand at a considerable rate, which can be majorly attributed to the growing incidence of gastroesophageal reflux disease (GERD) as well as the increasing adoption rate of H2-receptor antagonists.
Research shows that the growing adoption of proton-pump inhibitors is a major factor due to which the H2-receptor antagonists market is likely to witness sluggish growth over the forecast period. In terms of influencing factors, presence of generic OTC H2-receptor antagonists and prevalence of GERD and peptic ulcer population are the clear. A present, the disease trend observed around the world indicates that eastern countries are more prone to regurgitation-dominant GERD and western countries observe heartburn-dominant GERD.
The H2-receptor antagonists market has not been experiencing considerable growth over the past few years owing to the availability of generic medications, growth in the number of local players, as well as the adverse effects associated with the consumption of H2-receptor antagonists. There are severe health risks associated with the consumption of H2-receptor antagonists, which include headaches, fatigue, abdominal pain, diarrhea, and drowsiness. The use of H2-receptor antagonists for patients with renal difficulties, hepatic impairment, or patients who are aged 50 years, can lead to adverse effects to the central nervous system. Drug interactions with the use of H2-receptor antagonists may go wrong at times, and a therapeutic increase in gastric pH is likely to disrupt the mechanism of drugs that require an acidic environment for dissolution.
Evolving Adoption Patterns, Driven by Strong Alternative Competitors
Consumer preference has changed for H2-receptor antagonists, which limits the market growth for H2-receptor antagonists. The market is already experiencing tough competition from other valuable alternatives, and present effects associated with the consumption of these drugs makes it even worse for manufacturers to label their products. Advisory labels for H2-receptor antagonists is mandatory, however, the present physical differences among consumers can lead to difficulties that they are not aware of.
The demand-side trends, which show increasing access to affordable generic versions of treatment, are indicating low spending for treatment, which is offsetting the increasing spending on branded drugs. The adoption of H2-receptor antagonists has changed over the years with the introduction of Zantac, which is considered to be the first billion-dollar drug to face growing competition from proton-pump inhibitors. There are other occasionally used alternative drug types available for cases, which include potassium-competitive acid blockers, antacids, and cytoprotective agents.
Although the H2-receptor antagonists market is mature and highly competitive, most segments of the H2-receptor antagonists market are either saturated or nearing saturation. Extensive pricing competition among generic manufacturers facilitate a continuous demand growth, which is in relation to the adoption of H2-receptor antagonists. Most of the major players in the pharmaceutical industry are manufacturing proton-pump inhibitors.
The adoption and clinical benefits associated with proton-pump inhibitors are larger in number, hence, a smaller number of manufacturers are present in the H2-receptor antagonists market. Clinically better products with affordable pricing can still act as significant influencers for this H2-receptor antagonists market. In the face of global volatility, manufacturers gain profits due to the reliability, productivity, and awareness offered by loyal consumers.
Targeting countries for marketing H2-receptor antagonists is most important as the emergence and presence of generic manufacturers has led to a more competitive market structure. Moreover, entering a H2-receptor antagonists market with many local players providing drugs at a considerably low cost is a challenge for most of the global manufacturers.
At present, the global H2-receptor antagonists market is highly fragmented, with the presence of few global manufacturers and a large number of regional manufacturers. Some of the key H2-receptor antagonist manufacturers include Alembic Pharmaceuticals Ltd, Cipla Ltd., Torrent Pharmaceuticals Ltd., Sanofi S.A., Abbott, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Cadila Healthcare Ltd, and GlaxoSmithKline Plc.